

METHOD OF TREATING CANCER BY CONJUNCTIVE THERAPY WITH 2'-  
HALOMETHYLIDENE DERIVATIVES AND A S-PHASE OR M-PHASE  
SPECIFIC ANTINEOPLASTIC AGENT

5

BACKGROUND OF THE INVENTION

Neoplastic disease states in humans are recognized throughout the world as being serious and oftentimes life-threatening conditions. These neoplastic diseases, which 10 are characterized by rapidly-proliferating cell growth, have been and continue to be the subject of worldwide research efforts directed toward the identification of therapeutic agents which are effective in the treatment of patients suffering therefrom. Effective therapeutic agents can be 15 characterized as those which prolong the survivability of the patient, which inhibit the rapidly-proliferating cell growth associated with the neoplasm, or which effect a regression of the neoplasm. Research in this area is primarily focused toward identifying agents which would be 20 therapeutically effective in humans. Typically, compounds are tested for antineoplastic activity in small mammals, such as mice, in experiments designed to be predictive of antineoplastic activity not only in those animals but also in humans against specific neoplastic disease states.


25

Certain S-phase specific antimetabolites and M-phase specific vinca alkaloids are well known as effective

antineoplastic agents [See Corr, R. T., and Fritz, W. L., "CANCER CHEMOTHERAPY HANDBOOK", 1980, Elsevier North Holland, Inc., New York, New York and Calabresi, P., and Chabner, B. A., "CHEMOTHERAPY OF NEOPLASTIC DISEASES",  
5 Section XII, GOODMAN AND GILLMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 8th ed., 1990, Pergamon Press Inc., Elmsford, New York]. Cytarabine (ARA-C), fluorouracil (5-FU), mercaptopurine (6-MP), methotrexate (MTX), thioguanine (6-TG), hydroxyurea, prednisone, procarbazine and  
10 diglycoaldehyde are examples of antimetabolites with antineoplastic properties. Vincristine and vinblastine are examples of vinca alkaloids with antineoplastic properties. These agents are proven to be useful in the treatment of patients suffering from a variety of neoplastic disease  
15 states.

Certain 2'-halomethylidene derivatives of the formula

(1)




wherein

V is oxy, methylene, or thio,

X<sub>1</sub> and X<sub>2</sub> are each independently hydrogen or halogen,  
30 with the proviso that at least one of X<sub>1</sub> and X<sub>2</sub> is halogen,

B is a radical of the formula



wherein Y<sub>1</sub> is nitrogen, a CH group, a CCl group, a CBr group or a CNH<sub>2</sub> group; Y<sub>2</sub> and Y<sub>3</sub> are each independently nitrogen or a CH group; Y<sub>4</sub> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy or halogen; Y<sub>5</sub> is amino or C<sub>1</sub>-C<sub>4</sub> alkoxy; and Z is hydrogen, halogen, or NH<sub>2</sub>;

or a pharmaceutically acceptable salt thereof, such as (E)-2'-deoxy-2'-fluoromethylideneцитidine, are also well known as effective antineoplastic agents [European Patent Application Publication No. 0 372 268, published June 13, 1990]. These 2'-halomethylidene derivatives of formula (1) are ribonucleotide reductase inhibitors with potent antiproliferative and antitumor activity which are also useful in the treatment of patients suffering from a variety of neoplastic disease states.

It has now been found that in treating a patient afflicted with certain neoplastic disease states, conjunctive therapy with a 2'-halomethylidene derivatives of formula (1), such as (E)-2'-deoxy-2'-fluoromethylideneцитidine, and a S-phase specific antineoplastic antimetabolite or M-phase specific vinca alkaloid will provide a synergistic antineoplastic effect.

SUMMARY OF THE INVENTION

The present invention provides a method of treating a patient suffering from a neoplastic disease state comprising  
5 administering to said patient an effective antineoplastic amount of a 2'-halomethylidene derivative of formula (1) in conjunctive therapy with an effective antineoplastic amount of a S-phase or M-phase specific antineoplastic antimetabolite or vinca alkaloid.

10

More specifically, the present invention provides a method of treating a patient suffering from a neoplastic disease state comprising administering an effective antineoplastic amount of 2'-halomethylidene derivative of  
15 formula (1) in conjunctive therapy with an effective antineoplastic amount of cytarabine (ARA-C), fluorouracil (5-FU), mercaptopurine (6-MP), methotrexate (MTX), thioguanine (6-TG), hydroxyurea, prednisone, procarbazine, diglycoaldehyde, vincristine or vinblastine.

20

DETAILED DESCRIPTION OF THE INVENTION

As used herein, the term "halogen" or "halo-" refers to a fluorine, chlorine, bromine, or iodine atom and the term  
25 "nitrogen" refers to a trivalent nitrogen atom attached to two radicals. The term "C<sub>1</sub>-C<sub>4</sub> alkyl" refers to a saturated straight or branched chain hydrocarbyl radical of one to four carbon atoms and includes methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tertiary butyl and the like.  
30 The term "C<sub>1</sub>-C<sub>4</sub> alkoxy" refers to a C<sub>1</sub>-C<sub>4</sub> alkyl bearing an oxy group and includes methoxy, ethoxy, propoxy, butoxy and the like.

As used herein, the term "S phase specific agent" refers  
35 to those agents which exert their cytotoxic activity in the

S phase or DNA synthetic phase of the cell cycle. Included within the meaning of the term are agents which exert their cytotoxic effect during the S phase of the cell cycle and subsequently result in cell death. Examples of cytotoxic 5 agents in this class are the antimetabolites cytarabine (ARA-C), fluorouracil (5-FU), mercaptapurine (6-MP), methotrexate (MTX), thioguanine (6-TG), hydroxyurea, prednisone, procarbazine and diglycoaldehyde. Also included within the meaning of the term "S phase specific agent" are 10 agents which exert their cytotoxic effect during the S phase but result in cell death while the cell is in the M phase or mitosis phase of the cell cycle. Examples of cytotoxic agents in this class are the nitrosoureas and bleomycin.

15 As used herein, the term "M phase specific agent" refers to those agents which exert their cytotoxic activity in the M-phase or mitotic phase of the cell cycle. Included within the meaning of the term are agents which exert their cytotoxic effect during the M phase of the cell cycle and 20 subsequently result in cell death. Examples of cytotoxic agents in this class are the etoposide, vincristine and vinblastine.

2'-Halomethylidene derivatives of formula (1) can be  
25 prepared as described in European Patent Application  
Publication No. 0 372 268, published June 13, 1990. In  
order to illustrate the preparation of the 2'-  
halomethylidene derivatives of formula (1), the following  
example illustrating the preparation of (E)-2'-deoxy-2'-  
30 fluoromethylidenecytidine is provided. The example is  
illustrative only and is not intended to limit the invention  
in any way. All temperatures are in degrees Celsius and the  
following abbreviations are used: (g) is grams, (mol) is  
moles, (ml) is milliliters, (l) is liters, (lb/in<sup>2</sup>) is  
35 pounds per square inch, (TLC) is thin layer chromatography,

(THF) is tetrahydrofuran, (DMF) is dimethylformamide, (mp) is melting point, (mm/Hg) is pressure expressed as millimeters of mercury, and (bp) is boiling point.

5 EXAMPLE 1

(Z)- and (E)-2'-DEOXY-2'-FLUOROMETHYLIDENECYTIDINE

Step a: 4-Ethoxy-1-[(3,5-O-tetraisopropylidene)siloxan-1,3-diyl]-β-D-erythro-pentofuran-2-(2-fluoro-2-phenylsulfonylmethyldene)osyl]-2(1H)-pyrimidone

- 10 Prepare diethylfluoromethylphenylsulfonylphosphonate as follows: To a solution of fluoromethylphenyl sulfone (500 mg, 2.87 mmol) in dry THF (30 ml) which has been cooled to about -60°C in a dry 3-necked 100ml flask with stirring bar, argon inlet valve, thermometer and rubber septum, add  
15 diethyl chlorophosphate (500 mg, 0.42 ml, 2.87 mmol) via syringe. To this mixture, add a solution of 1.65 M lithium diisopropylamide in cyclohexane (3.48 ml, 5.74 mmol) via syringe and follow the formation of diethylfluoromethylphenylsulfonylphosphonate by gas-liquid chromatography  
20 (GLC).

To the diethylfluoromethylphenylsulfonylphosphonate solution above add a solution of 4-ethoxy-1-[(3,5-O-tetraisopropylidene)siloxan-1,3-diyl]-2-keto-β-D-erythro-pentofuranosyl]-2(1H)-pyrimidone (732 mg, 2 mmol) in dry THF (about 5 ml) and allow the reaction mixture to warm to room temperature overnight under an argon atmosphere. Pour the mixture into a saturated, ice-cold solution of ammonium chloride and extract the mixture with ethyl acetate (30 times, 75 ml each time). Combine the organic layers, dry with anhydrous magnesium sulfate, and evaporate to dryness. Chromatograph the residue on a silica gel flash column eluting with ethyl acetate/hexane (1/1, v/v) to provide the title compound.

Step b: 4-Ethoxy-1-[ $\beta$ -D-erythro-pentofuran-2-(2-fluoro-2-phenylsulfonylmethylidene)osyl]-2(1H)-pyrimidone

To a solution of 1.0 M tetrabutylammonium fluoride in THF (2.2 ml, 2.2 mmol) add 4-ethoxy-1-[ $\beta$ -(3,5-O-tetraisopropyldisiloxan-1,3-diyl)-D-erythro-pentofuran-2-(2-fluoro-2-phenylsulfonylmethylidene)osyl]-2(1H)-pyrimidone (668 mg, 1 mmol) and stir the mixture at room temperature for 2 hours. Neutralize the mixture with acetic acid, add flash silica gel to the mixture and evaporate to dryness *in vacuo*. Apply the residue to a flash silica gel column and elute with chloroform/ethanol (20/1, v/v) to provide the title compound.

Step c: (Z)- and (E)-2'-Deoxy-2'-fluoromethylidene cytidine

15 To a solution of 4-ethoxy-1-[ $\beta$ -D-erythro-pentofuran-2-(2-fluoro-2-phenylsulfonylmethylidene)osyl]-2(1H)-pyrimidone (854 mg, 2 mmol) in 10% aqueous THF (100 ml) under a nitrogen atmosphere, add aluminum amalgam (made from 0.04 gm aluminum in 2% aqueous HgCl<sub>2</sub>). Stir and vent the mixture while refluxing for 2 hours. Filter the mixture and evaporate most of the THF *in vacuo*. Extract the residue with ethyl acetate (3 times, 25 ml each time), combine the organic layers and dry with anhydrous Na<sub>2</sub>SO<sub>4</sub>. Evaporate to dryness *in vacuo* and apply the residue to a flash silica gel column and elute with chloroform/ethanol (9/1, v/v) to provide (Z)- and (E)-4-ethoxy-1-[ $\beta$ -D-erythro-pentofuran-2-(2-fluoromethylidene)osyl]-2(1H)-pyrimidone as a mixture of geometric isomers.

30 Heat a solution of (Z)- and (E)-4-ethoxy-1-[ $\beta$ -D-erythro-pentofuran-2-(2-fluoromethylidene)osyl]-2(1H)-pyrimidone (858 mg, 3 mmol) in methanolic ammonia (10 ml, saturated at 0°C) in a sealed tube at 100°C for 2 days. Evaporate the solution to dryness and separate the (Z) and (E) isomers of the title compound by chromatography by applying the residue

S65260 - 2260000000

to a column packed with Dowex 1-X2 (OH<sup>-</sup> form) and eluting with methanol.

The antineoplastic antimetabolites, such as cytarabine  
5 (ARA-C), fluorouracil (5-FU), mercaptopurine (6-MP),  
methotrexate (MTX), thioguanine (6-TG), hydroxyurea,  
prednisone, procarbazine and diglycoaldehyde and the  
antineoplastic vinca alkaloids, such as vincristine and  
vinblastine, are readily available and their use as  
10 antineoplastic agents is well known and appreciated in the  
art [For example, See Corr, R. T., and Fritz, W. L., "CANCER  
CHEMOTHERAPY HANDBOOK", 1980, Elsevier North Holland, Inc.,  
New York, New York and Calabresi, P., and Chabner, B. A.,  
"CHEMOTHERAPY OF NEOPLASTIC DISEASES", Section XIII, GOODMAN  
15 AND GILLMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 8th  
ed., 1990, Pergamon Press Inc., Elmsford, New York].

The present invention provides a method of treating a patient suffering from a neoplastic disease state comprising  
20 conjunctive therapy with an effective antineoplastic amount of a 2'-halomethylidene of formula (1) and an effective antineoplastic amount of a S-phase specific antineoplastic antimetabolite or M-phase specific vinca alkaloid. This conjunctive therapy unexpectedly provides a synergistic  
25 antineoplastic effect.

As used herein, the term "patient" refers to a warm-blooded animal such as a mammal which is afflicted with a neoplastic disease state. It is understood that dogs, cats,  
30 rats, mice, horses, bovine cattle, sheep, and humans are examples of animals within the scope of the meaning of the term.

The term "neoplastic disease state" as used herein  
35 refers to an abnormal state or condition characterized by

rapidly proliferating cell growth or neoplasm. Neoplastic disease states for which conjunctive therapy according to the present invention will be particularly useful include: Leukemias such as, but not limited to, acute lymphoblastic, 5 chronic lymphocytic, acute myeloblastic and chronic myelocytic; Carcinomas, such as, but not limited to, those of the cervix, oesophagus, stomach, small intestines, brain, colon and lungs; Sarcomas, such as, but not limited to, osteosarcoma, osteosarcoma, lepoma, liposarcoma, hemangioma and 10 hemangiosarcoma; Melanomas, including amelanotic and melanotic; and mixed types of neoplasias such as, but not limited to carcinosarcoma, lymphoid tissue type, follicular reticulum, cell sarcoma and Hodgkin's disease. Of course, one skilled in the art will recognize that not every 15 combination of conjunctive therapy according to the present invention will be equally effective against each of the neoplastic disease states. Selection of the most appropriate combination is within the ability of one of ordinary skill in the art and will depend on a variety of 20 factors including assessment of results obtained in standard animal cancer models and the effectiveness of the individual agents as monotherapy in treating particular neoplastic disease states.

25 For example, conjunctive therapy with a 2'-  
halomethylidene derivatives of formula (1) and cytarabine  
will be particularly effective in the treatment of a patient  
afflicted with acute granulocytic and acute lymphocytic  
leukemias. Conjunctive therapy with a 2'-halomethylidene  
30 derivative of formula (1) and hydroxyurea will be  
particularly effective in the treatment of a patient  
afflicted with chronic granulocytic leukemia, polycythemia  
vera, essential thrombocythosis and malignant melanoma.  
Conjunctive therapy with a 2'-halomethylidene derivative of  
35 formula (1) and prednisone will be particularly effective in

the treatment of a patient afflicted with acute and chronic lymphocytic leukemias, non-Hodgkin's lymphomas, Hodgkin's disease and breast carcinoma. Conjunctive therapy with a 2'-halomethylidene derivative of formula (1) and  
5 methotrexate will be particularly effective in the treatment of a patient afflicted with acute lymphocytic leukemia, choriocarcinoma, mycosis fungoides, breast, head and neck carcinoma, and lung osteogenic sarcoma. Conjunctive therapy with a 2'-halomethylidene derivative of formula (1) and  
10 fluorouracil will be particularly effective in the treatment of a patient afflicted with breast, colon, stomach, pancreas, ovary, head and neck carcinoma, urinary bladder carcinoma and premalignant skin lesions. Conjunctive therapy with a 2'-halomethylidene derivative of formula (1)  
15 and mercaptopurine will be particularly effective in the treatment of a patient afflicted with acute lymphocytic, acute granulocytic and chronic granulocytic leukemias. Conjunctive therapy with a 2'-halomethylidene derivative of formula (1) and thioguanine will be particularly effective  
20 in the treatment of a patient afflicted with acute granulocytic, acute lymphocytic, and chronic granulocytic leukemias. Conjunctive therapy with a 2'-halomethylidene derivative of formula (1) and procarbazine will be particularly effective in the treatment of a patient  
25 afflicted with Hodgkin's disease. Conjunctive therapy with a 2'-halomethylidene derivative of formula (1) and vincristine will be particularly effective in the treatment of a patient afflicted with acute lymphocytic leukemia, neuroblastoma, Wilms' tumor, rhabdomyosarcoma, Hodgkin's  
30 disease and small-cell lung carcinoma. Conjunctive therapy with a 2'-halomethylidene derivative of formula (1) and vinblastine will be particularly effective in the treatment of a patient afflicted with Hodgkin's disease, non-Hodgkin's lymphomas, breast and testis carcinoma.

In effecting treatment of a patient afflicted with a neoplastic disease state as described above, a 2'-halomethylidene derivative of formula (1) is administered in conjunctive therapy with a S-phase specific antineoplastic 5 antimetabolite or M-phase specific vinca alkaloid. As used herein, the term "conjunctive therapy" contemplates co-administration of a 2'-halomethylidene derivative of formula (1) along with the S-phase specific antineoplastic antimetabolite or M-phase specific vinca alkaloid. This co- 10 administration may take place at essentially the same time, it may take place sequentially, or it may take place alternately.

In providing co-administration at essentially the same time, the courses of treatment with a 2'-halomethylidene derivative of formula (1) and the selected S-phase specific antineoplastic antimetabolite or M-phase specific vinca alkaloid run essentially concomitantly. In providing sequential co-administration, a full course of treatment of one of the agents is terminated and then followed by a full course of treatment of the other. In providing alternate co-administration, a partial course of treatment of one of the agents is terminated and then followed by a partial course of treatment of the other in an alternating manner until a full treatment of each agent is administered. When the 2'-halomethylidene derivative of formula (1) and the selected S-phase specific antineoplastic antimetabolite or M-phase specific vinca alkaloid are co-administered in a sequential or an alternate manner, it is generally preferred to administer the 2'-halomethylidene derivative of formula (1) first and the S-phase specific antineoplastic antimetabolite or M-phase specific vinca alkaloid last.

In effecting the conjunctive therapy according to the present invention, it is preferred to co-administer the 2'-

halomethylidene derivative of formula (1) and the selected S-phase specific antineoplastic antimetabolite or M-phase specific vinca alkaloid in a sequential or an alternate manner. It is most preferred to co-administer the 2'-  
5 halomethylidene derivative of formula (1) and the selected S-phase specific antineoplastic antimetabolite or M-phase specific vinca alkaloid in a sequential manner.

As used herein, the term "effective antineoplastic amount" refers to an amount which is effective, upon single or multiple dose administration to the patient, in controlling the growth of the neoplasm or in prolonging the survivability of the patient beyond that expected in the absence of such treatment. As used herein, "controlling the growth" of the neoplasm refers to slowing, interrupting, arresting or stopping its growth and does not necessarily indicate a total elimination of the neoplasm.

An effective antineoplastic amount of a 2'-halomethylidene derivative of formula (1) is expected to vary from about 10 milligram per kilogram of body weight per day (mg/kg/day) to about 100 mg/kg/day and preferably will be about 5 mg/kg/day to about 50 mg/kg/day.

25 The effective antineoplastic amounts of the various S-  
phase specific antineoplastic antimetabolites and M-phase  
specific vinca alkaloids are well known and appreciated in  
the art. For example, an effective antineoplastic amount of  
cytarabine (ARA-C) is expected to vary from about 1  
30 mg/m<sup>2</sup>/day to about 200 mg/m<sup>2</sup>/day. An effective  
antineoplastic amount of fluorouracil (5-FU) is expected to  
vary from about 6 mg/m<sup>2</sup>/day to about 800 mg/m<sup>2</sup>/day. An  
effective antineoplastic amount of mercaptapurine (6-MP) is  
expected to vary from about 2.5 mg/m<sup>2</sup>/day to about 700  
35 mg/m<sup>2</sup>/day. An effective antineoplastic amount of

methotrexate (MTX) is expected to vary from about 2.5 mg/m<sup>2</sup>/day to about 30 mg/m<sup>2</sup>/day. An effective antineoplastic amount of thioguanine (6-TG) is expected to vary from about 2 mg/kg/day to about 3 mg/kg/day. An effective  
5 antineoplastic amount of hydroxyurea is expected to vary from about 20 mg/kg/day to about 80 mg/kg/day. An effective antineoplastic amount of prednisone is expected to vary from about 15 mg/m<sup>2</sup>/day to about 100 mg/m<sup>2</sup>/day. An effective antineoplastic amount of procarbazine is expected to vary  
10 from about 1 mg/kg/day to about 4 mg/kg/day. An effective antineoplastic amount of diglycoaldehyde is expected to vary from about 0.25 mg/kg/day to about 5 mg/kg/day. An effective antineoplastic amount of vincristine is expected to vary from about 0.4 mg/M<sup>2</sup>/week to about 2 mg/M<sup>2</sup>/week. An  
15 effective antineoplastic amount of vinblastine is expected to vary from about 4.0 mg/m<sup>2</sup>/week to about 2 mg/m<sup>2</sup>/day.

In effecting treatment of a patient afflicted with a disease state described above, the 2'-halomethylidene  
20 derivatives of formula (1) can be administered in any form or mode which makes the compound bioavailable in effective amounts, including oral and parenteral routes. For example, it can be administered orally, subcutaneously, intramuscularly, intravenously, transdermally, intranasally,  
25 rectally, and the like. Oral administration is generally preferred. One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the particular circumstances, including the disease state to be treated, the stage of the  
30 disease, the form of administration of the selected S-phase specific antineoplastic antimetabolite or vinca alkaloid, the manner of co-administration selected, and the like.

In effecting treatment of a patient afflicted with a  
35 disease state described above, the 2'-halomethylidene

PAPERS 025727-002900

derivatives of formula (1), can be administered in combination with the various S-phase specific antineoplastic antimetabolites or M-phase specific vinca alkaloids in the proportions of antineoplastic amount of a 2'-halomethylidene derivative of formula (1) to antineoplastic amount of a S-phase or M-phase specific agent in the range of about 1:0.1 to about 1:50, more preferably in the range of about 1:1 to about 1:20 and most preferably in the range of about 1:1 to about 1:10.

10

The 2'-halomethylidene derivatives of formula (1) can be administered alone or in the form of a pharmaceutical composition in combination with pharmaceutically acceptable carriers or excipients, the proportion and nature of which are determined by the solubility and chemical properties of the 2'-halomethylidene derivatives of formula (1), the chosen route of administration, and standard pharmaceutical practice. The 2'-halomethylidene derivative of formula (1), while effective itself, may be formulated and administered in the form of its pharmaceutically acceptable acid addition salt for purposes of stability, convenience of crystallization, increased solubility and the like.

The selected S-phase specific antineoplastic antimetabolite or M-phase specific vinca alkaloid can be administered in a manner as is well known and accepted for the particular agent. For example, cytarabine, fluorouracil, methotrexate, thioguanine, hydroxyurea, procarbazine, mercaptopurine (as its sodium salt), vinblastine and vincristine may be administered intravenously. Mercaptopurine, methotrexate, thioguanine, hydroxyurea, prednisone, procarbazine and diglycoaldehyde may be administered orally. Methotrexate may also be administered via intramuscular, intraarterial and intrathecal routes.

The following examples are provided in order to illustrate the method of use of the present invention. These examples are intended to be illustrative only and are not to be construed to limit the scope of the invention in any way.

Example 2

Synergistic Antitumor Activity of A Combination of MDL 101,731 and Ara-C Against B16 Melanoma in Mice.

Inject B16 melanoma cells ( $1 \times 10^5$  cells/mouse) subcutaneously on day 0. Administer compounds i.p. once daily as indicated. Sacrifice the animals on day 15, dissect the tumors and weigh.

Table 1  
Antitumor Activity against B16 Melanoma

Treatment	Tumor Weight (g) (Mean $\pm$ S.D.a)	% Inhibition
Control	$2.6 \pm 0.5$	-
101,731b (5 mg/kg, day 1-7)	$2.4 \pm 0.9$	10
Ara-C (10 mg/kg, day 7-14)	$3.6 \pm 0.8$	0
101,731 + Ara-C	$1.0 \pm 0.3$	59

a S.D. = Standard Deviation

b101,731 = (E)-2'-deoxy-2'-fluoromethylideneцитidine

Example 3

Synergistic Antitumor Activity of A Combination of MDL  
101,731 and Ara-C Against Lewis Lung Carcinoma in Mice

- 5 Inject 3LL cells ( $1 \times 10^5$ /mouse) s.c. on day 0. Administer compounds i.p., once daily as indicated. Sacrifice animals on day 15, dissect the tumors and weigh. Also count pulmonary metastatic foci.

Table 2  
Antitumor Activity against Lewis Lung Carcinoma

	Treatment	Tumor Weight (g) (Mean $\pm$ S.D.a)	% Inhibition	No. of Foci (Mean $\pm$ S.D.a)	% Inhibition
10	Control	$3.5 \pm 0.4$	-	$11.3 \pm 4$	-
15	101,731b (5 mg/kg, day 1-7)	$2.8 \pm 0.6$	20	$15.5 \pm 6$	0
20	Ara-C (10 mg/kg, day 7-14)	$3.83 \pm 0.8$	0	$14.6 \pm 5$	0
	101,731 + Ara-C	$1.12 \pm 0.3$	69	0	100

a S.D. = Standard Deviation

b 101,731 = (E)-2'-deoxy-2'-fluoromethylideneцитidine

25

30

35

Example 4

Synergistic Antiproliferative Activity of MDL 101,731 in Combination with S Phase Specific Antitumor Agents Against HeLa Cells

5

Plate HeLa cells ( $2 \times 10^3$  cells/well) and allow to grow for 18 hours. Treat with MDL 101,731 (15ng/mL) for 24 hours. Wash the compound and expose cells to the indicated drugs for another 72 hours. Determine the cell viability by 10 a colorimetric assay, essentially as described by Carmichael et al. [Cancer Res. 47, 936 (1987)], whereby the cellular reduction of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is measured. Treatment with 15 MDL 101,731 alone as described did not show any effect on the growth of the tumor cells.

Calculate  $IC_{50}$  values for the individual treatments as well as for the combined treatments of MDL 101,731 with the various other agents. The  $IC_{50}$  values at the various 20 concentrations of test agents are presented in Table 3.

Table 3  
Antiproliferative Activity of 101,731 in Combination with S Phase Specific Anti-tumor Agents Against HeLa Cells

25

Drug	Drug Alone $IC_{50}$ ( $\mu$ g/mL)	Drug + 101,731 <sup>a</sup> $IC_{50}$ ( $\mu$ g/mL)
Cytosine Arabinoside (Ara-C)	13.7	3.2
5-Fluorouracil (5Fu)	41.1	18.9

30

<sup>a</sup>101,731 = (E)-2'-deoxy-2'-fluoromethylideneцитidine

Table 3  
Antiproliferative Activity of 101,731 in Combination with S  
Phase Specific Anti-tumor Agents Against HeLa Cells

Drug	Drug Alone $IC_{50}$ ( $\mu$ g/mL)	Drug + 101,731 <sup>a</sup> $IC_{50}$ ( $\mu$ g/mL)
Vinblastine (VLB)	86.7	13.6

<sup>a</sup>101,731 = (E)-2'-deoxy-2'-fluoromethylideneцитidine

10

15

20

25

30

35